News

Public · Published

Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals announced positive results from cohort 2 of the pivotal PROGRESS study of Atebrioz (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. Atebrioz reduced HO lesion volume, improved joint mobility at week 24, and showed no new HO lesions or safety signals.

Published:

Updated:

What happened

Mirum Pharmaceuticals announced positive results from cohort 2 of the pivotal PROGRESS study of Atebrioz (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva. Atebrioz reduced HO lesion volume, improved joint mobility at week 24, and showed no new HO lesions or safety signals.

Confirmed

Global impact / market context

Positive pediatric data support expanding Atebrioz to younger patients, a move that could widen the treated population and add revenue if approved. The company plans a supplemental new drug application, which means a filing to add a new use to an existing approval, in the first half of 2027.

Analyst inference

For investors, the trial outcome lowers clinical risk for the pediatric label expansion but does not guarantee approval. Attention shifts to regulatory review and launch costs, which could raise capital spending before any added sales arrive.

Analyst inference

What to watch

  1. Mirum plans to submit a supplemental new drug application in the first half of 2027 to expand the Atebrioz indication to ages 6 to under 12. Confirmed
  2. Watch whether regulators accept the filing and grant approval, since a supplemental application proposes a new use and is not an automatic right to market. Proposed
  3. Track launch preparation and spending on pediatric commercialization, because added costs could pressure cash available before new revenue materializes. Analyst inference

Evidence

  • Original source link unavailable